Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Biogen Idec 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Biogen Idec 3Q

Growth in the quarter was driven primarily by Tysabri sales, up 21% to $207 million.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec 3Q

3Q Revenues: $1.1 billion (+3%)

3Q Earnings:$279.6 million (+35%)

YTD Revenues: $3.3 billion (+7%)

YTD Earnings: $671.1 million (+15%)

Comments: Growth in the quarter was driven primarily by Tysabri sales, up 21% to $207 million. Avonex sales were $580 million (+1%). Revenues for the quarter included $284 million from Biogen Idec’s co-promotion arrangement with Genentech for Rituxan. Revenues from other products in the quarter were $15 million, compared to $14 million in 3Q08. Royalty revenues in the quarter were flat at $35 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters